TWI253349B - Transdermally administered tolterodine as anti-muscarinic agent for the treatment of overactive bladder - Google Patents

Transdermally administered tolterodine as anti-muscarinic agent for the treatment of overactive bladder Download PDF

Info

Publication number
TWI253349B
TWI253349B TW088114752A TW88114752A TWI253349B TW I253349 B TWI253349 B TW I253349B TW 088114752 A TW088114752 A TW 088114752A TW 88114752 A TW88114752 A TW 88114752A TW I253349 B TWI253349 B TW I253349B
Authority
TW
Taiwan
Prior art keywords
tolterodine
transdermal administration
type
administration according
compound
Prior art date
Application number
TW088114752A
Other languages
English (en)
Chinese (zh)
Inventor
Jacobsen Lene Orup
Bo Kreilgard
Ulla Hoeck
Helle Kristensen
Original Assignee
Pfizer Health Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20412370&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TWI253349(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Health Ab filed Critical Pfizer Health Ab
Application granted granted Critical
Publication of TWI253349B publication Critical patent/TWI253349B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TW088114752A 1998-08-27 1999-08-27 Transdermally administered tolterodine as anti-muscarinic agent for the treatment of overactive bladder TWI253349B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9802864A SE9802864D0 (sv) 1998-08-27 1998-08-27 Transdermally administered tolterodine as antimuscarinic agent for the treatment of overactive bladder

Publications (1)

Publication Number Publication Date
TWI253349B true TWI253349B (en) 2006-04-21

Family

ID=20412370

Family Applications (1)

Application Number Title Priority Date Filing Date
TW088114752A TWI253349B (en) 1998-08-27 1999-08-27 Transdermally administered tolterodine as anti-muscarinic agent for the treatment of overactive bladder

Country Status (13)

Country Link
US (2) US6517864B1 (https=)
EP (1) EP1105111B1 (https=)
JP (1) JP2002523446A (https=)
AT (1) ATE405254T1 (https=)
AU (1) AU758399B2 (https=)
CA (1) CA2341063C (https=)
DE (1) DE69939382D1 (https=)
ES (2) ES2353765T3 (https=)
NZ (1) NZ509928A (https=)
SE (1) SE9802864D0 (https=)
TW (1) TWI253349B (https=)
WO (1) WO2000012070A1 (https=)
ZA (1) ZA200002488B (https=)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998003067A1 (en) * 1996-07-19 1998-01-29 Gunnar Aberg S(-)-tolterodine in the treatment of urinary and gastrointestinal disorders
EP0957073A1 (en) * 1998-05-12 1999-11-17 Schwarz Pharma Ag Novel derivatives of 3,3-diphenylpropylamines
SE9802864D0 (sv) * 1998-08-27 1998-08-27 Pharmacia & Upjohn Ab Transdermally administered tolterodine as antimuscarinic agent for the treatment of overactive bladder
PT1031346E (pt) 1999-01-27 2002-09-30 Idea Ag Vacinacao nao invasiva atraves da pele
SI1031347T1 (en) 1999-01-27 2002-10-31 Idea Ag Transnasal transport/immunisation with highly adaptable carriers
DE19922662C1 (de) 1999-05-18 2000-12-28 Sanol Arznei Schwarz Gmbh Transdermales therapeutisches System (TTS) Tolterodin enthaltend
WO2001001962A1 (en) * 1999-07-05 2001-01-11 Idea Ag. A method for the improvement of transport across adaptable semi-permeable barriers
DE19932651A1 (de) * 1999-07-13 2001-01-18 Hexal Ag Transdermales therapeutisches System zur Anwendung von Tolterodin
JP2005513080A (ja) * 2001-12-20 2005-05-12 フェムファーマ， インコーポレイテッド 薬物の膣送達
JP2006515026A (ja) * 2003-01-02 2006-05-18 フェムファーマ ホールディング カンパニー， インコーポレイテッド 乳房の疾患および障害の処置のための薬学的調製物
US9173836B2 (en) 2003-01-02 2015-11-03 FemmeParma Holding Company, Inc. Pharmaceutical preparations for treatments of diseases and disorders of the breast
US20040191345A1 (en) * 2003-03-26 2004-09-30 Fredrik Nicklasson New formulations and use thereof
DE10315917A1 (de) * 2003-04-08 2004-11-18 Schwarz Pharma Ag Hochreine Basen von 3,3-Diphenylpropylaminmonoestern
JP5548329B2 (ja) * 2003-08-04 2014-07-16 杏林製薬株式会社 経皮吸収型製剤
WO2006015299A2 (en) * 2004-07-30 2006-02-09 Microchips, Inc. Multi-reservoir device for transdermal drug delivery and sensing
WO2006082888A1 (ja) * 2005-02-03 2006-08-10 Kyorin Pharmaceutical Co., Ltd. 経皮吸収型製剤
CN101340884A (zh) 2005-10-19 2009-01-07 曼尼·马纳舍·辛格尔 用于治疗多汗症的方法
EA023147B1 (ru) * 2006-04-13 2016-04-29 Тева Фармасьютикалс Интернешнл Гмбх Трансдермальный пластырь для лечения мигрени
AU2012261753B2 (en) * 2006-04-13 2015-03-05 Teva Pharmaceuticals International Gmbh Transdermal methods and systems for the delivery of anti-migraine compounds
US7803778B2 (en) 2006-05-23 2010-09-28 Theracos, Inc. Glucose transport inhibitors and methods of use
US7893053B2 (en) 2006-06-16 2011-02-22 Theracos, Inc. Treating psychological conditions using muscarinic receptor M1 antagonists
US8748419B2 (en) 2006-06-16 2014-06-10 Theracos, Inc. Treating obesity with muscarinic receptor M1 antagonists
US20080153789A1 (en) * 2006-12-26 2008-06-26 Femmepharma Holding Company, Inc. Topical administration of danazol
US20080193766A1 (en) * 2007-02-13 2008-08-14 Northern Nanotechnologies Control of Transport to and from Nanoparticle Surfaces
JP5583003B2 (ja) 2007-04-02 2014-09-03 セラコス・インコーポレイテッド ベンジルグルコシド誘導体およびその用途
EP2175843B1 (en) 2007-08-08 2014-10-08 Inventia Healthcare Private Limited Extended release compositions comprising tolterodine
NZ583369A (en) 2007-08-23 2011-08-26 Theracos Inc Benzylbenzene derivatives and methods of use
KR101188333B1 (ko) * 2008-02-20 2012-10-09 에스케이케미칼주식회사 안정성이 우수하고 경피제로 유용한 톨테로딘 결정성산부가염
US20090297591A1 (en) * 2008-05-30 2009-12-03 Orient Pharma Co., Ltd. Compositions And Methods For The Transdermal Delivery Of Pharmaceutical Compounds
US20110223204A1 (en) * 2008-06-04 2011-09-15 Bradford J Duft Treatment of pain with gap junction modulation compounds
US8155737B2 (en) * 2008-06-19 2012-04-10 Nupathe, Inc. Pharmacokinetics of iontophoretic sumatriptan administration
US8366600B2 (en) * 2008-06-19 2013-02-05 Nupathe Inc. Polyamine enhanced formulations for triptan compound iontophoresis
AU2009270936B2 (en) 2008-07-15 2014-12-18 Theracos, Inc. Deuterated benzylbenzene derivatives and methods of use
CN103910702A (zh) 2008-08-22 2014-07-09 泰拉科斯有限公司 制备sglt2抑制剂的方法
WO2010068483A2 (en) 2008-11-25 2010-06-17 University Of Rochester Mlk inhibitors and methods of use
CA2764526A1 (en) 2009-06-24 2010-12-29 Christine Kritikou The use of spinosyns and spinosyn compositions against diseases caused by protozoans, viral infections and cancer
KR20110001103A (ko) 2009-06-29 2011-01-06 에스케이케미칼주식회사 보관 안정성이 향상된 톨테로딘 함유 경피 투여 조성물
US20110003000A1 (en) * 2009-07-06 2011-01-06 Femmepharma Holding Company, Inc. Transvaginal Delivery of Drugs
CN105796533A (zh) * 2009-08-10 2016-07-27 泰华制药国际有限公司 用离子电渗疗法治疗恶心和偏头痛的方法
US20110087153A1 (en) * 2009-10-13 2011-04-14 Angelov Angel S Transdermal Methods And Systems For The Delivery Of Rizatriptan
IL210279A0 (en) 2009-12-25 2011-03-31 Dexcel Pharma Technologies Ltd Extended release compositions for high solubility, high permeability acdtive pharmaceutical ingredients
KR101746204B1 (ko) 2010-02-18 2017-06-13 에스케이케미칼주식회사 피부 투과가 개선된 톨테로딘의 경피 투여용 조성물
KR20110094858A (ko) * 2010-02-18 2011-08-24 에스케이케미칼주식회사 피부 자극이 감소한 톨테로딘의 경피 투여용 조성물
US20130053357A1 (en) * 2010-04-28 2013-02-28 Hisamitsu Pharmaceutical Co., Inc. Skin irritation suppressant and transdermal preparation
JP6086326B2 (ja) 2010-05-24 2017-03-01 ユニヴァーシティー オブ ロチェスター 二環式ヘテロアリールキナーゼ阻害剤および使用方法
WO2011153712A1 (en) 2010-06-12 2011-12-15 Theracos, Inc. Crystalline form of benzylbenzene sglt2 inhibitor
WO2012017892A1 (ja) 2010-08-03 2012-02-09 久光製薬株式会社 貼付剤及びその粘着力増強方法
EP2654757A1 (en) 2010-12-22 2013-10-30 Entarco SA The use of spinosyns and spinosyn compositions as local anesthetics and as antiarrhythmic agents
EP3502236B1 (en) 2011-02-18 2023-08-23 The Scripps Research Institute Directed differentiation of oligodendrocyte precursor cells to a myelinating cell fate
CA2868334C (en) 2011-12-27 2020-03-10 Teikoku Seiyaku Co., Ltd. Tolterodine-containing adhesive patch
CA2868534A1 (en) 2012-03-27 2013-10-03 Coda Therapeutics, Inc. Compositions and treatments based on cadherin modulation
JP2015520754A (ja) 2012-05-18 2015-07-23 オタゴ イノベーション リミテッド 創傷治癒のための組合せ治療および組成物
US10758494B2 (en) 2012-06-12 2020-09-01 KM Transderm Ltd. Rivastigmine-containing adhesive patch
US9895320B2 (en) 2012-09-28 2018-02-20 KM Transderm Ltd. Transdermal patch with different viscosity hydrocarbon oils in the drug layer and the adhesive layer
CN104884059B (zh) 2012-11-30 2018-08-10 罗切斯特大学 用于hiv/aids治疗的混合谱系激酶抑制剂
CN103142465B (zh) * 2013-03-19 2014-10-22 长春健欣生物医药科技开发有限公司 一种托特罗定成膜水凝胶制剂及其制备方法
EP3119394B1 (en) 2014-03-19 2021-05-12 Curza Global LLC Compositions and methods comprising 2-(acylamino)imidazoles
US9987361B1 (en) 2014-12-29 2018-06-05 Noven Pharmaceuticals, Inc. Compositions and method for sustained drug delivery by active transdermal technology
JP2020512981A (ja) 2017-03-31 2020-04-30 カーザ グローバル，リミティド ライアビリティ カンパニー 置換２−アミノイミダゾールを含む組成物と方法
JP2021534196A (ja) 2018-08-23 2021-12-09 シージェン インコーポレイテッド 抗ｔｉｇｉｔ抗体
EP4185310A4 (en) * 2020-07-23 2024-09-04 Kimberly-Clark Worldwide, Inc. METHOD OF MODULATING THE BLADDER MICROBIOME TO IMPROVE BLADDER HEALTH
WO2022098972A1 (en) 2020-11-08 2022-05-12 Seagen Inc. Combination-therapy antibody drug conjugate with immune cell inhibitor
EP4320160A1 (en) 2021-04-09 2024-02-14 Seagen Inc. Methods of treating cancer with anti-tigit antibodies
WO2024191807A1 (en) 2023-03-10 2024-09-19 Seagen Inc. Methods of treating cancer with anti-tigit antibodies

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5382600A (en) 1988-01-22 1995-01-17 Pharmacia Aktiebolag 3,3-diphenylpropylamines and pharmaceutical compositions thereof
ZA933349B (en) * 1992-05-13 1994-06-15 Alza Corp Transdermal administration of oxybutynin
WO1998003067A1 (en) 1996-07-19 1998-01-29 Gunnar Aberg S(-)-tolterodine in the treatment of urinary and gastrointestinal disorders
PT877600E (pt) * 1996-08-09 2004-02-27 Alcon Mfg Ltd Sistemas conservantes para composicoes farmaceuticas contendo ciclodextrinas
SE9802864D0 (sv) * 1998-08-27 1998-08-27 Pharmacia & Upjohn Ab Transdermally administered tolterodine as antimuscarinic agent for the treatment of overactive bladder

Also Published As

Publication number Publication date
US20030124179A1 (en) 2003-07-03
US7008637B2 (en) 2006-03-07
CA2341063C (en) 2008-02-12
AU5891999A (en) 2000-03-21
ZA200002488B (en) 2001-05-16
ATE405254T1 (de) 2008-09-15
AU758399B2 (en) 2003-03-20
CA2341063A1 (en) 2000-03-09
US6517864B1 (en) 2003-02-11
JP2002523446A (ja) 2002-07-30
WO2000012070A1 (en) 2000-03-09
EP1105111B1 (en) 2008-08-20
DE69939382D1 (de) 2008-10-02
EP1105111A1 (en) 2001-06-13
SE9802864D0 (sv) 1998-08-27
NZ509928A (en) 2003-08-29
ES2353765T3 (es) 2011-03-04
ES2310942T3 (es) 2009-01-16

Similar Documents

Publication Publication Date Title
TWI253349B (en) Transdermally administered tolterodine as anti-muscarinic agent for the treatment of overactive bladder
JP2002523446A5 (https=)
CN102781473B (zh) 外用药物组合物
US5378730A (en) Permeation enhancer comprising ethanol and monoglycerides
KR101016838B1 (ko) 로티고틴 투여를 위한 향상된 경피 송달 시스템
CN101032474B (zh) 一种治疗或预防神经系统疾病的雷沙吉兰透皮贴片及其制备方法
US8246980B2 (en) Transdermal delivery system
CN103476404B (zh) 包含活性剂层和活性剂转化层的透皮组合物
JP2003511425A (ja) 二元粘着性経皮薬物デリバリーシステム
CN106659702A (zh) 透皮递送体系
JP2008507495A (ja) 活性本体の経皮送達用デバイス
JPH0667835B2 (ja) 医薬組成物
KR101017882B1 (ko) 가교형 피부용 점착제
KR101016914B1 (ko) 향상된 경피 송달 시스템
KR100929560B1 (ko) 그라니세트론을 함유한 매트릭스 형태의 경피 흡수제
EP1244431A1 (en) Transdermal administration of reboxetine
WO2021098791A1 (zh) 一种含有美金刚的透皮贴剂
CN105147642B (zh) 一种含福莫特罗或其富马酸盐的透皮贴剂
JPWO2018199018A1 (ja) 経皮吸収型製剤およびその製造方法
WO2024067731A1 (zh) S-氯胺酮经皮组合物及其制备方法和应用
CN116712413A (zh) 一种普拉克索透皮贴剂
CN120114421A (zh) 褪黑素透皮贴剂及其制备方法
JP2021113231A (ja) 経皮投与製剤

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees